Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Phase 2

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Matching placebo of ofatumumab
Drug: Ofatumumab

First Posted Date: 2017-08-15

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT03249714

Locations: 🇷🇺
Novartis Investigative Site, Novosibirsk, Russian Federation

Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)

Phase 2

Completed

Conditions: Cocaine-related Disorder

Interventions: Drug: Placebo
Drug: AFQ056

First Posted Date: 2017-08-08

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT03242928

Locations: 🇨🇭
Novartis Investigative Site, Zuerich, Switzerland

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2

Withdrawn

Conditions: Carcinoma
Non-Small-Cell Lung Cancer

Interventions: Drug: INC280

First Posted Date: 2017-08-07

Last Posted Date: 2018-07-26

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03240393

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: QAW039

First Posted Date: 2017-07-21

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 704

Registration Number: NCT03226392

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

Phase 2

Active, not recruiting

Conditions: Autoimmune Hepatitis

Interventions: Biological: VAY736
Other: Placebo

First Posted Date: 2017-07-14

Last Posted Date: 2024-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT03217422

Locations: 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
University of California Davis Medical Center, Sacramento, California, United States

and more 2 locations

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: QAW039
Drug: Placebo

First Posted Date: 2017-07-12

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 675

Registration Number: NCT03215758

Locations: 🇹🇷
Novartis Investigative Site, Yenisehir/Izmir, Turkey

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Phase 2

Terminated

Conditions: NSCLC, Non Small Cell Lung Cancer
RCC, Renal Cell Cancer
Head and Neck Cancer
Pancreatic Cancer
TNBC, Triple Negative Breast Cancer
Melanoma
mCRPC, Metastatic Castration Resistant Prostate Cancer
Urothelial Cancer
DLBCL, Diffused Large B Cell Lymphoma
MSS, Microsatellite Stable Colon Cancer

Interventions: Drug: NIR178
Drug: PDR001

First Posted Date: 2017-07-05

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 315

Registration Number: NCT03207867

Locations: 🇺🇸
H Lee Moffitt Cancer Center and Research Institute ., Tampa, Florida, United States
🇺🇸
University of California, Los Angeles, Santa Monica, California, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

and more 3 locations

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

Phase 2

Completed

Conditions: Obese Patients With Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: LIK066
Drug: Placebo

First Posted Date: 2017-07-02

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 107

Registration Number: NCT03205150

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

Phase 2

Terminated

Conditions: Hereditary Hemochromatosis

Interventions: Drug: Deferasirox FCT
Procedure: Phlebotomy

First Posted Date: 2017-06-29

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT03203850

Locations: 🇨🇭
Novartis Investigative Site, Lugano, Switzerland

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

Phase 2

Completed

Conditions: Advanced Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma

Interventions: Drug: Pazopanib

First Posted Date: 2017-06-27

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT03200717

Locations: 🇬🇧
Novartis Investigative Site, Preston, United Kingdom
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy